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Objectives: Increased cardiovascular risk in rheumatoid arthritis (RA) is well established. Examining
traditional cardiovascular risk factors alone underestimates cardiovascular risk in RA. Systematic
inﬂammation, measured by erythrocyte sedimentation rate or C-reactive protein is also a major risk
factor. However, the contribution of traditional cardiovascular risk factors (such as obesity and hyper-
lipidaemia) compared to inﬂammation is uncertain in psoriatic arthritis (PsA) and RA. We examine the
incidence of major adverse cardiac events (MACE) among patients with RA, PsA psoriasis, and controls
adjusting for risk factors, inﬂammation and disease modifying anti-rheumatic drug treatment, to better
deﬁne cardiovascular risk.
Methods: Using the Secure Anonymised Information Linkage databank, comprising routinely collected
Welsh health data from 1999 to 2013, the incidence and ﬁrst occurrence of a MACE in individuals with RA
(n ¼ 8650), PsA (n ¼ 2128) and psoriasis (n ¼ 24,630) compared to controls (n ¼ 11,87,706) was
investigated.
Results: Traditional cardiovascular risk factors are higher in RA, PsA and psoriasis than controls. After
adjusting for these factors, additional cardiovascular risk was only signiﬁcantly increased in female RA
patients (HR ¼ 1.3; 95% CI: 1.0–1.7; p ¼ 0.05) and psoriasis (HR ¼ 1.2; 95% CI: 1.0–1.4; p ¼ 0.02) but not
statistically signiﬁcant for PsA (HR ¼ 1.5; 95% CI: 0.9–2.5; p ¼ 0.13). ESR and CRP were increased in
patients with RA but not in patients with psoriasis.
Conclusion: Additional increased cardiovascular risk was observed in female RA and psoriasis but not
PsA. Systematic inﬂammation is higher in RA but not psoriasis, indicating that there are varying
mediators of cardiovascular risk across these conditions.
& 2018 The Authors. Published by Elsevier HS Journals, Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Key messages
• There is an increased cardiovascular risk in womenwith RA and
men and women with psoriasis but not for PsA.
• There are additional, unidentiﬁed risk factors of MACE in
psoriasis.
• Cardiovascular risk strategies need to be disease speciﬁc for
inﬂammatory arthritis conditions and psoriasis.r HS Journals, Inc. This is an open
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Patients with inﬂammatory arthritis such as rheumatoid arthri-
tis (RA), have a higher incidence of cardiovascular events [1,2].
Importantly, cardiovascular risk in RA cannot be explained by
traditional cardiovascular risk factors alone [3] and systemic
inﬂammation is independently associated with increased cardio-
vascular risk [4]. Consequently, cardiovascular risk scores used
routinely in the general population, such as the Framingham risk
score underestimate risk in patients with RA [5]. The QRISK2 score
includes RA as an independent risk factor and inﬂates 10-year
cardiovascular risk estimates for those with RA by 1.38 times in
males and 1.5 times in females. This is comparable to those
recommended by European League Against Rheumatism (EULAR)
in patients with RA, which recommends a multiplication factor ofaccess article under the CC BY-NC-ND license
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general population [6]. In RA, systematic review and meta-analysis
suggested treatment with tumour necrosis factor inhibitors and
methotrexate could reduce cardiovascular events, however, data
on the effect of DMARDs and biologic treatment on cardiovascular
risk in psoriasis and psoriatic arthritis (PsA) were limited [7]. PsA is
another common chronic inﬂammatory arthritis occurring in a
third of patients with psoriasis. A meta-analysis concluded that
ischaemic heart disease, peripheral vascular disease and athero-
sclerosis are increased in patients with psoriasis and traditional
cardiovascular risk factors such as diabetes, hypertension, dyslipi-
daemia, high body mass index and metabolic syndrome were also
more common in these patients [8–10]. Moreover, comorbidities
were associated with more severe psoriasis.
Whether increased cardiovascular risk in psoriasis and PsA is
due to more prevalent traditional cardiovascular risk factors
remains unclear. Studies demonstrating an increased risk of
cardiovascular disease, when controlling for traditional cardiovas-
cular risk factors have tended to be retrospective, population-
based studies [11–14]. Limitations of these studies include missing
data on family history of ischaemic heart disease, use of NSAIDs
and systemic inﬂammation. Furthermore, case–control approaches
frequently adopted by such studies may not be as strong as cohort
studies.
A systematic review of cardiovascular comorbidities in PsA
reviewed 28 eligible studies [15]. Data from these studies were
conﬂicting with only one study reporting increased cardiovascular
mortality. Four studies (4810 PsA patients in total) found increased
cardiovascular comorbidity, however, only one of these was a
prospective study with 453 patients [16].
A meta-analysis was carried out by Alamanos et al. and found a
wide variation in the annual incidence of PsA, ranging from 0.1 to
23.1 cases per 100,000 (median 6.4/100,000) inhabitants with
large differences between countries. The mean age at diagnosis
varied between 40.7 and 52 years (median ¼ 47.7 years). Preva-
lence rates also varied between 1 case per 100,000 (Japan) to 420
per 100,000 (Italy) inhabitants [17]. Depending on the deﬁnitions
used (e.g., diagnostic codes, patient self-reporting, rheumatologist
diagnosis and classiﬁcation criteria) prevalence and incidence
rates of PsA in psoriasis patients range from 6% to 41%.
More recently, a systematic review and meta-analysis found
PsA to be an independent risk factor for cardiovascular disease.
However, this study did not take into account traditional cardio-
vascular risk factors [18]. Other studies using surrogate markers,
such as ﬂow-mediated occlusion and carotid intima-media thick-
ness, found increased prevalence of atherosclerosis. However,
many studies have also found that traditional cardiovascular risk
factors: hypertension, diabetes and dyslipidaemia were also more
common in patients with PsA [19–22]. A single-centre study, based
on hospital data, found cardiovascular comorbidities and tradi-
tional cardiovascular risk factors were more common in PsA
compared to psoriasis patients [23]. In a prospective cohort study
of 158 PsA patients followed-up from time of diagnosis, the 10-
year cumulative cardiovascular events increased by 17% [24].
Similar to RA, Framingham risk score signiﬁcantly underestimated
risk in these patients.
Two inception cohorts using the Clinical Practice Research
Datalink have provided opposing results; Parisi et al. [25] found
no increased risk of major cardiovascular events while Degran
et al. [26] reported an increased risk for severe psoriasis patients.
Recently, a large prospective, UK-based study on data from The
Health Improvement Network dataset found that cardiovascular
events by 40–50% in patients with RA and severe psoriasis
(severity deﬁned by DMARD usage) [27]. In patients with PsA,
cardiovascular risk increased by 20%, which was signiﬁcantly
lower than patients with RA or severe psoriasis. In contrast topatients with psoriasis taking DMARDs, patients with PsA taking
DMARDs have lower risk of cardiovascular events. However, it is
not clear if this suggests an effect of DMARDs on cardiovascular
risk or on disease severity. Similar to previous studies, family
history of cardiovascular diseases was not available. In addition,
data on ESR or CRP were not available, so the impact of systemic
inﬂammation and DMARDs could not be assessed [2]. Recently, a
German study investigating RA has demonstrated that ESR and
CRP are signiﬁcantly elevated in the 6 months prior to an MI
compared to controls. There was also a strong association between
higher CRP and MI. Furthermore, treatment with prednisone,
biologic or other DMARDs was not associated with risk of MI [28].
Here we examine the cardiovascular events in patients with RA,
PsA and psoriasis using the Secure Anonymised Information
Linked (SAIL) Databank in Wales, which includes nation-wide
health data from primary and secondary care, including family
history of cardiovascular disease and ESR as linking health data
provides a more robust, multi-source perspective which enhances
analysis compared to using isolated datasets [29].Methods
Study design and patients
The SAIL databank [30] is a data repository which allows
person-based data linkage across datasets. This databank includes
Welsh GP data, hospital in- and out-patient records, as well as
mortality data collected by the Ofﬁce of National Statistics (ONS).
SAIL holds over a billion anonymised records. It uses a split-ﬁle
approach to ensure anonymisation and overcome issues of con-
ﬁdentiality and disclosure in health-related data warehousing.
Demographic data is sent to a partner organisation, NHS Wales
Informatics Service, where identiﬁable information is removed;
clinical data are sent directly to the SAIL Databank and an
individual is assigned an encrypted anonymised linking ﬁeld
(ALF). The ALF is used to link anonymised individuals across
datasets, facilitating longitudinal analysis of an individual’s jour-
ney through multiple health, education and social datasets [31].
Data collected by GPs is captured via Read Codes (5-digit codes
related to diagnosis, medication and process of care codes) [32].
Hospital inpatient and outpatient data are collected in the Patient
Episode Database for Wales, which contains clinical information
regarding patients’ hospital admissions, discharges, diagnoses and
operations using the International Classiﬁcation of Diseases (ICD-
10) clinical coding system. The ONS Mortality dataset contains
demographic data, place of death and underlying cause of death
(also ICD-10).
Patients were identiﬁed from GP records from the SAIL data-
bank. Individuals who had at least one READ Code consistent with
RA, PsA or psoriasis (Supplementary Table 1) in their GP records
were assigned to their respective condition groups. Only those
who were over the age of 18 at ﬁrst mention, which was
considered as the diagnosis date, were included. Data was linked
at the person-level to hospital admissions and ONS mortality data
to explore cardiovascular events.
The PsA group comprised individuals positive for PsA codes
within their GP record but could additionally have psoriasis codes
in their medical history. The psoriasis group had codes for
psoriasis only. The RA group may present with a skin disorder
initially and so individuals who had RA codes were assigned to the
RA group (whether or not they also had psoriasis and PsA codes
present). The control population comprised of individuals who did
not present with RA, PsA or psoriasis codes. A random date was
generated for the control population that could be used as a
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1999 to December 2013 for optimum data coverage purposes.
Ethical approval
Data held in the SAIL databank are anonymised and therefore,
no ethical approval is required. All data contained in SAIL has the
permission from the relevant Caldicott Guardian or Data Protec-
tion Ofﬁcer. SAIL-related projects are required to obtain Informa-
tion Governance Review Panel (IGRP) approval.
Major adverse cardiac events (MACEs)
Primary outcome measures were MACEs, namely, myocardial
infarction (MI), cerebrovascular accident (CVA), and associated
deaths identiﬁed from the GP, hospital admissions and ONS data-
sets (see Supplementary Tables 2 and 3 for coding deﬁnitions).
Covariates of interest and confounding factors
Traditional cardiovascular risk factors included age at diagnosis,
age at study start, gender, BMI, smoking status, hypertension,
hyperlipidaemia, diabetes, previous cardiovascular disease and
family history of cardiovascular disease were collected from the
GP records where relevant READ Codes were present or calculated
from available data (e.g., height and weight for BMI). Measure of
inﬂammation was based on ESR. Potential confounders, such as
medications (non-steroidal anti-inﬂammatory drugs (NSAIDs),
DMARDs, oral corticosteroids and topical steroids) statistical
analyses. All covariates and confounders were identiﬁed from the
GP records and the codes used are available in Supplementary
Tables 4–15.
Statistical analysis
Descriptive statistics were used to examine age, sex and
covariate distribution for RA, PsA psoriasis, and the control
population. A Cox proportional model was employed to calculate
hazard ratios for each group. Censoring occurred when a patient
died, lost to follow-up (moving out of Wales, so that health records
were incomplete) or reaching the end of the study.Table 1
Baseline characteristics
Control (n ¼ 11,87,706)
Age at study start (conﬁdence intervals) 39.0 (16.3)
(39–39)
Mean age at diagnosis/random date (SD) 50 (17.2)
(50–50)
Male 49% (585,049/11,87,422)
(49.2–49.4)
Baseline BMI 25.5 (5.1)
(25.5–25.5)
Smoker 21.2% (2,51,423/11,87,706)
(21.1–21.2)
Statin use 0.8% (9275/11,87,706)
(0.8–0.8)
ESR (SD) 8.5 (12.8)
(8.5–8.5)
ESR and statin use were not included in the statistical model due to being on the MACUnivariate analyses were performed to determine signiﬁcance
and candidate variables to be included in the Cox proportional
hazard model. Signiﬁcant covariates (p value of 0.25 or less) were
incorporated into the model (Supplementary Tables 16–18).
A subgroup analysis was performed which involved individuals
who had no MACE events prior to diagnosis of RA, PsA or psoriasis.
Likelihood ratio tests were used to determine the signiﬁcance
of interactions. Missing data were treated as missing.Results
The population consisted of 8650 RA, 2128 PsA and 24,630
psoriasis patients identiﬁed from GP records. The control popula-
tion comprised 1,187,706 individuals present in the GP without
codes for RA, PsA or psoriasis. The mean age of the study
population was approximately 50 years. The characteristics of
patients and the control group at baseline are reported in Table 1.
The prevalence of co-morbidities and medications taken by the
group are presented in Table 2. Individuals with RA tended to take
more medication, with 68.2% and 54.3% having ever taken
DMARDs and oral steroids, respectively. Hypertension, diabetes
and hyperlipidaemia tended to be more prevalent in the RA, PsA
and psoriasis patients. At the time of diagnosis, smoking was more
prevalent in patients with RA and psoriasis but a similar rate of
smoking was observed among patients with PsA and the control
population. Interestingly, individuals who ever smoked were lower
in patients with PsA than control, RA or psoriasis. Previous
ischaemic heart disease was more prevalent in RA and psoriasis
but lower in patients with PsA. Family history of ischaemic heart
disease is more common in RA, psoriasis and PsA and use of
NSAIDs, DMARDs and steroids were also higher in these patients
compared to controls.
In the control population, the incidence rate of MI was 1.9 per
1000 person-years follow-up and 3.0 per 1000 person-years for
stroke. Incidence rates of MI, stroke and MACE were higher in
patients with RA and psoriasis but not in PsA (Table 3).
After controlling for the traditional cardiovascular risk factors
MACEs were statistically signiﬁcantly increased for individuals
with psoriasis (HR ¼ 1.2; 95% CI: 1.0–1.4; p ¼ 0.02) but there
was no evidence of an increase for RA and PsA patients (Table 4)
when compared to controls. However, when incorporating genderRA (n ¼ 8650) PsA (n ¼ 2128) Psoriasis (n ¼ 24,630)
48.1 (15.0) 38.5 (13.2) 40.2 (15.4)
(47.8–48.4) (37.9–39.1) (40–40.4)
59.6 (14.6) 50.3 (13.1) 51.4 (16.2)
(59.3–59.9) (49.7–50.9) (51.2–51.6)
32% (2780/8650) 47% (998/2127) 49% (12,037/24,627)
(31.1–33.1) (44.8–49.1) (48.3–50.0)
26.8 (5.5) 27.8 (5.9) 26.5 (5.4)
(26.7–26.9) (27.5–28.1) (26.4–26.6)
24.6% (2129/8650) 21.9% (467/2128) 27.9% (6877/24,630)
(23.7–25.5) (20.2–23.8) (27.4–28.5)
1.6% (137/8650) 0.9% (19/2128) 1.1% (278/24,630)
(1.3–1.9) (0.6–1.4) (1.0–1.3)
11.0 (17.1) 12.1 (15.4) 8.9 (14.1)
(10.6–11.4) (11.4–12.8) (8.7–9.1)
E pathway.
Table 2
Smoking, comorbidity and medication history throughout patient record
Control (n ¼ 11,87,706) RA (n ¼ 8650) PsA (n ¼ 2128) Psoriasis (n ¼ 24,630)
Ever smoked (conﬁdence intervals) 50.9% (604,705/11,87,706) 50.1% (4410/8650) 46.7% (994/2128) 50% (12,391/24,630)
(50.8–51.0) (50.2–52.0) (44.6–48.8) (49.7–50.9)
Hyperlipidemia 7.3% (86,258/11,87,706) 13.9% (1202/8650) 12.6% (268/2128) 11.4% (2796/24,630)
(7.2–7.3) (13.2–14.6) (11.3–14.1) (11.0–11.8)
Diabetes 7.8% (92,345/11,87,706) 14.1% (1220/8650) 13.1% (278/2128) 11.9% (2936/24,630)
(7.7–7.8) (13.4–14.9) (11.7–14.6) (11.5–12.3)
Hypertension 21.6% (256,665/11,87,706) 39.7% (3434/8650) 33.3% (709/2128) 29.9% (7368/24,630)
(21.5–21.7) (38.7–40.7) (31.4–35.4) (29.4–30.5)
Ischaemic heart disease 6.7% (79,811/11,87,706) 14.5% (1258/8650) 7.8% (166/2128) 9.6% (2371/24,630)
(6.7–6.8) (13.8–15.3) (6.7–9.0) (9.3–10.0)
Family history of ischaemic heart disease 14.1% (167,577/11,87,706) 18.5% (1604/8650) 22.3% (474/2128) 18.5% (4562/24,630)
(14.1–14.2) (17.7–19.4) (20.6–24.1) (18.0–19.0)
NSAIDs 61.5% (730,476/11,87,706) 92.9% (8034/8650) 92.6% (1970/2128) 79.9% (19,680/24,630)
(61.4–61.6) (92.3–93.4) (91.4–93.6) (79.4–80.4)
DMARDs 1.2% (13735/11,87,706) 68.2% (5896/8560) 57.1% (1214/2128) 7.5% (1847/24,630)
(1.1–1.2) (67.9–69.9) (54.9–59.1) (7.2–7.8)
Oral steroids 13.5% (159,918/11,87,706) 54.3% (4699/8650) 33.8% (720/2128) 22.6% (5566/24,630)
(13.4–13.5) (53.3–55.4) (31.9–35.9) (22.1–23.1)
Topical steroids 33.1% (393,324/11,87,706) 53.8% (4656/8650) 80.3% (1708/2128) 84.4% (20,778/24,630)
(33.0–33.2) (52.8–54.9) (78.5–81.9) (83.9–84.8)
R. Cooksey et al. / Seminars in Arthritis and Rheumatism ] (2018) ]]]–]]]4interactions by condition, RAwas associated with increased MACEs
in females (HR ¼ 1.3; 95% CI: 1.0–1.7; p ¼ 0.05). The greatest
predictor of MACE was a previous MACE event (Supplementary
Tables 19 and 20).
Subgroup analysis, which removed individuals who had MACE
events prior to diagnosis, demonstrated that RA (HR ¼ 1.2; 95% CI:
1.0–1.3; p ¼ 0.04) and psoriasis patients (HR ¼ 1.1; 95% CI:
1.0–1.3; p ¼ 0.03) had an increased risk of MACE in comparison
to controls (Supplementary Table 21) but not for patients with
PsA compared to controls. Furthermore, MACE remained signiﬁ-
cantly increased in patients with RA and psoriasis after the
addition of NSAIDs, DMARDs, topical steroids and oral steroids
into the statistical model. Likelihood odds ratio tests found no
statistical signiﬁcant interaction between DMARDs and MACEs by
condition, meaning that DMARDs did not have signiﬁcantly differ-
ent effects within individuals with RA, PsA or psoriasis compared
to controls (data not shown). When controlling for age, gender and
BMI there was a signiﬁcant increase in the mean level of ESR in
individuals with RA (regression coefﬁcient ¼ 4.9; 95% CI: 2.7–7.0;
p ≤ 0.001) but not psoriasis or psoriatic arthritis compared to
controls.
Sensitivity analysis included all individuals aged 50 years or
below which demonstrated no increased risk of MACE for indi-
viduals with RA and PsA, however, the risk of MACE wasTable 3
Incidence of MI, stroke and MACE (excluding individuals who have had events pre-diag
MI
cases
Person years
follow-up
Incidence rate per
1000 PY (95% CI)
Stroke
cases
Person
follow-
Control 13,708 73,67,124 1.9 (1.8–1.9) 21,936 73,71,51
RA 241 57,005 4.2 (3.7–4.8) 340 57,09
PsA 24 14,801 1.6 (1.1–2.4) 19 14,80
Psoriasis 373 165,063 2.3 (2.0–2.5) 569 165,20signiﬁcantly increased for individuals with psoriasis (HR ¼ 1.3;
95% CI: 1.1–1.6; p ¼ 0.02) (Table 5).Discussion
To our knowledge, this is the ﬁrst study to demonstrate that
patients with psoriasis, similar to patients with RA, have increased
MACEs even after controlling for traditional cardiovascular risk
factors including family history of ischaemic heart disease. This
suggests additional factors contribute to the development of
cardiovascular events in these conditions. MACEs were highest in
patients with RA and these patients also had higher levels of
inﬂammation, as indicated by increased ESR. In PsA, ESR levels
were not signiﬁcantly increased which may be explained in part by
the individuals with RA being a more homogenous group of older
females. Indeed, research has shown that elevated ESR is a
signiﬁcant predictor of cardiovascular risk in women with PsA
[33] and so suggests a gender effect. Furthermore, psoriatic
arthritis is a heterogeneous disease with differential effects on
inﬂammatory markers; one of the limitations of the study is lack of
data on the type of PsA which may explain the lack of statistical
signiﬁcant difference in ESR between PsA and controls. However,
our ﬁndings replicate those reported by Paramarta el al. [34], whonosis)
years
up
Incidence rate per
1000 PY (95% CI)
MACE
cases
Person years
follow-up
Incidence rate per
1000 PY (95% CI)
9 3.0 (2.9–3.0) 33,456 73,67,124 4.5 (4.5–4.6)
3 5.4 (5.4–6.6) 548 57,005 9.6 (8.8–10.5)
1 1.3 (0.8–2.0) 43 14,801 2.9 (2.2–3.9)
0 3.4 (3.2– 3.7) 879 165,063 5.3 (5.0–5.7)
Table 4
Hazard ratio of developing a major adverse cardiac event (MACE) by condition
compared to control population with gender as an interaction term
Hazard ratio 95% CI
RA 1.0 0.8–1.3
PsA 1.5 0.9–2.5
Psoriasis⁎ 1.2 1.0–1.4
Interaction
RA × female⁎ 1.3 1.0–1.7
PsA × female 0.5 0.2–1.1
Psoriasis × female 0.9 0.7–1.1
Adjusted for
Female 0.7 0.6–0.7⁎⁎
Age at diagnosis 1.2 1.1–1.2⁎⁎
Age at study start 0.9 0.9–0.9⁎⁎
DMARD 1.1 1.0–1.3⁎
NSAIDS 2.1 1.9–2.2⁎⁎
Topical steroids 0.9 0.9–0.9⁎⁎
Oral steroids 1.1 1.1–1.2⁎⁎
BMI 1.0 1.0–1.0
Smoker 1.2 1.2–1.2⁎⁎
Hyperlipidemia 1.2 1.2–1.3⁎⁎
Diabetes 1.4 1.3–1.4⁎⁎
Hypertension 1.3 1.2–1.3⁎⁎
Ischaemic heart disease in family 1.1 1.1–1.1⁎⁎
⁎ p o 0.05.
⁎⁎ p o 0.01.
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RA, inﬂammation levels may explain the higher MACE events.
However, inﬂammation was not higher for those with psoriasis
when compared with controls and so may not explain the higher
levels of MACE in the psoriasis population. These ﬁndings are
consistent with previous data in RA but are novel for psoriasis.
Our data showed that MACE was not higher in those with PsA
after controlling for traditional cardiovascular risk factors. Previous
ﬁndings from cross-sectional studies [9,10,35], and more recently,
two population-based longitudinal studies have found increased
cardiovascular events in patients with PsA. One population study
using data from the UK reported a 20% increased risk of MACEs in
PsA although this study did not include family history of ischaemicTable 5
Hazard ratio of developing a major adverse cardiac event (MACE) by condition
compared to control population in individuals of 50 years old or younger
Hazard ratio 95% CI
RA 1.0 0.7–1.5
PsA 1.2 0.6–2.3
Psoriasis⁎ 1.3 1.1–1.6
Adjusted for
Female 0.5 0.5–0.5⁎⁎
Age at diagnosis 1.1 1.1–1.1⁎⁎
Age at study start 1.0 1.0–1.0⁎
DMARD 1.2 1.0–1.6
NSAIDS 2.1 1.9–2.5⁎⁎
Topical steroids 0.9 0.8–1.0⁎
Oral steroids 1.2 1.1–1.3⁎⁎
BMI 1.0 1.0–1.0
Smoker 1.5 1.3–1.6⁎⁎
Hyperlipidemia 1.3 1.1–1.4⁎⁎
Diabetes 1.6 1.4–1.8⁎⁎
Hypertension 1.4 1.3–1.6⁎⁎
Ischaemic heart disease in family 1.1 1.0–1.2⁎
⁎ p o 0.05.
⁎⁎ p o 0.01.heart disease as a risk factor [27]. Another study from Norway [36]
found increased prevalence of self-reported angina pectoris,
hypertension and history of percutaneous coronary intervention
but not for MI or CVA in patients with PsA, although cardiovascular
risk factors were higher in these patients (higher prevalence of
hypertension, tobacco smoking and increased BMI). This is in
agreement with our ﬁndings which shows that traditional cardi-
ovascular risk factors such as hypertension, diabetes, increased
BMI and family history of ischaemic heart disease are more
prevalent in patients with psoriasis and PsA as well as RA. In our
study, traditional cardiovascular risk factors fully account for MACE
in PsA, suggesting adjustment in cardiovascular risk score is
unnecessary for patients with PsA.
Potential explanations for the discrepancies in ﬁndings sur-
rounding cardiovascular risk may be associated with the differing
methodologies employed. For instance, cross-sectional, case–con-
trol, and cohort studies have investigated cardiovascular risk and
the approach used may explain different results.
Case deﬁnitions may also vary from study to study, for instance,
previous studies using electronic health records have stratiﬁed
patients using phototherapy and differing DMARDs as surrogate
markers for disease severity which may not accurately classify the
level of disease activity [25–27]. Patients must assess the beneﬁts
and risks to starting treatments, in particular, systemic and bio-
logic therapies which may cause adverse effects. Patient centred
care and education means that an individual with psoriasis is
informed to make a personal decision regarding their treatment
and an absence of DMARD therapies in their patient record may
reﬂect this choice, rather than a proxy for disease severity. In fact,
a great dissatisfaction has been reported with current psoriasis
treatment options [37–39], which may cause resistance to agreeing
to these medications.
Previous studies have recruited patients attending secondary
care while we studied patients in primary care, so we may have
also included more patients with both milder and more severe
disease, potentially representing individuals with the condition
more appropriately. Cross-sectional studies conducted with
patients recruited from secondary care, are more likely to include
patients with increased comorbidities and severe diseases than
patients considered in our study. This may be particularly impor-
tant for PsA, which is a heterogeneous condition. Disease varies
from spondyloarthropathy, mono/oligo-arthritis or polyarthritis.
The Swedish Early Psoriatic Arthritis Register found that ESR
and CRP were higher in RA than PsA [40], which we have also
found. Patients with polyarticular disease have higher ESR and CRP
compared to patients with axial disease; whilst patients with
mono-/oligo-arthritis have intermediate values. However, in psor-
iasis the ESR and CRP are usually normal and so not routinely
assessed. In our study we also found no difference between
controls and psoriasis.
The fact that PsA patients had lower cardiovascular risk than
patients with psoriasis is surprising given most patients with PsA
suffer from psoriasis. This may be explained by higher usage of
DMARDs, particularly methotrexate which can lower cardiovascu-
lar risk. However, in this study we found no interaction between
DMARDs and PsA in terms of predicting cardiovascular risk. This
differs from the study by Ogdie et al. [27], who found an
association between DMARD usage and higher cardiovascular risk
in patients with psoriasis or PsA. Ogdie et al. used DMARD as a
surrogate for disease severity. However, this is not ideal as differ-
ent DMARDs may have different impact on cardiovascular risk. For
instance, methotrexate is associated with reduced cardiovascular
risk in patients with RA, while acitretin is associated with hyper-
lipidaemia. Thus, difference in speciﬁc DMARDs used in psoriasis
and PsA may contribute to why are results are not in agreement
with Ogdie et al.
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Strengths
A considerable strength of the study is the linkage between the
GP and hospital admissions datasets, allowing the robust and
reliable clinical picture of the population. This study also includes
data on family history of ischaemic heart disease and ESR. MACE-
related hospital admissions and associated deaths were identiﬁed
using ICD-10 codes from hospital admissions, not relying on
algorithms or text comments from health records and as such,
MACEs are conﬁrmed in the datasets. Utilising routine data we
include a nation-wide, large-scale population that does not result
in a small, potentially unrepresentative sample [11,24,41,42],
restrict the sample to a single gender, nor rely on self-reported
diagnoses [43]; linking routine health data means that a repre-
sentative cohort can be created with conditions and events
conﬁrmed in one or all of the datasets. The routine data also allow
more patients to be assessed, when compared to studies that use
individuals who fulﬁl certain disease speciﬁc criteria, which may
change or be updated in the future. Diagnostic criteria parameters
for psoriatic arthritis and rheumatoid arthritis [44,45] (there is no
speciﬁc criteria for psoriasis, at present) may not be reliably
available in routine data. Strictly adhering to criteria may cause
early disease or less severe cases to be missed, even though the
disease in these individuals could progress to meet all aspects of a
given criteria over time. This would result in a limited and biased
sample that is likely to have more severe disease and therefore
increased risk of comorbidities, including cardiac events, thereby
over-inﬂating cardiac risk estimations. To utilise routine data to its
full potential, it makes sense in this instance to allow clinical
coding of conditions to deﬁne the populations, especially since
primary care and secondary care physicians are qualiﬁed in
identifying conditions, as our prevalence rates conﬁrm; our
0.71% rate of RA is comparable to the 1% cited elsewhere [46],
while our 0.2% rate of PsA is in line with general population
estimates of 0.3–1% [47] and ﬁnally, our 2.0% rate of psoriasis was
similar to UK ﬁndings of 1.9% [48].
Furthermore, the incidence rate of MI observed in our study
was 1.9 per 1000 person (Table 2) which is comparable to the rate
of 1.5 reported for men and 0.6 reported for women living in
England in 2010 [49] but our rate of stroke was 3.0 per 1000
person years, which is somewhat higher than the rates for men
(1.8) and women (1.4) in England during 2007 [49].Limitations
It is possible that there is some ﬂuidity between the classiﬁed
groups; as psoriasis and psoriatic arthritis frequently coexist,
individuals who are assigned to the psoriasis group based on
psoriasis Read Codes could actually have PsA which has not yet
been detected. In addition, identifying individuals with
arthropathy from GP records means that their condition may
or may not be conﬁrmed by a rheumatologist. It is worthy to
note that our classiﬁcation of PsA patients differs from those
used previously. In this study, patients assigned to the PsA
group could also have codes for psoriasis. The reason for this is
that PsA and psoriasis frequently coexist and excluding indi-
viduals who present with both PsA and psoriasis codes from
analysis could potentially omit 30% of the PsA population [50].
Furthermore, another study has demonstrated that over a half
of psoriasis patients who received systemic or biologic thera-
pies at study start had an inﬂammatory arthritis diagnosis by
the end of follow-up [25].
We can also expect a degree of missing data when using
routine data for research purposes.We did not have a true marker for disease severity within the
data and could not assess its role in cardiovascular risk in this
study. However, as per previous studies we explored the role of
DMARDs as a surrogate marker for severity and found no inter-
action between DMARDs and cardiovascular risk.
There was limited data on the usage of biologic therapies;
however, ﬁndings suggest that biologic usage is not associated
with risk of MI in RA. Further work to explore the role of the
biologics will be useful to understand the true risk of cardiovas-
cular disease in inﬂammatory arthritis and psoriasis.Conclusions
Cardiovascular events were increased in female RA patients and
in individuals with psoriasis after adjusting for traditional cardi-
ovascular risk factors. The increased risk of cardiovascular events
in RA may be attributed to inﬂammation. In psoriasis there are
other additional unidentiﬁed risk factors for cardiovascular events
and this needs more investigation. In PsA, risk of MACE appears to
be attributed to increased prevalence of traditional cardiovascular
risk factors. Cardiovascular risk score adjustment, such as recom-
mended by EULAR for RA may not be applicable for PsA. Distinct
factors are responsible for cardiovascular events in different
chronic inﬂammatory diseases and as such cardiovascular risk
reduction strategies need to be disease speciﬁc and not standard
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